ALHC Alignment Healthcare LLC

Assenagon Asset Management S.A. significantly reduced its stake in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 98.6% in the third quarter, reducing its holdings to 26,072 shares valued at $455,000. Despite this, institutional investors collectively own 86.19% of the stock, with several other large institutions increasing their positions. The company reported a 43.5% increase in quarterly revenue and beat EPS estimates but remains unprofitable, while insiders have been net sellers.

Despite Alignment Healthcare, Inc. (ALHC) experiencing a 25% share price jump in the last month and impressive revenue growth of 47% in the past year, investors remain unconvinced, as reflected by its P/S ratio closely matching the industry average of 1.3x. Even with analyst forecasts projecting 27% annual revenue growth, significantly outpacing the industry's 5.9%, the company's valuation indicates investor skepticism about its ability to meet these high expectations. This suggests a potential buying opportunity for those who believe in the analysts' optimistic outlook.

Alignment Healthcare, Inc. (ALHC) shareholders have seen a 25% share price increase in the last month, contributing to a 92% annual gain. Despite this surge and strong revenue growth, the company's P/S ratio remains close to the industry median, suggesting that investors are not fully convinced that the strong revenue performance will continue or that future growth expectations will be met. Analysts, however, forecast significantly higher revenue growth for Alignment Healthcare compared to the broader industry.

Voya Investment Management LLC significantly increased its stake in Alignment Healthcare (NASDAQ:ALHC) in the third quarter by purchasing an additional 1,210,930 shares, bringing its total holdings to 3,196,297 shares valued at approximately $55.8 million, representing a 1.61% stake. Despite a 43.5% year-over-year revenue increase to $993.7 million and beating EPS estimates, Alignment Healthcare remains unprofitable and trades near $20 with a "Moderate Buy" consensus analyst rating. Over the past quarter, company insiders sold 842,157 shares, while institutional investors now own 86.19% of the company.

Alignment Healthcare (NASDAQ:ALHC) shareholders have seen a significant 25% price jump recently, contributing to a 92% annual gain. Despite strong revenue growth of 47% last year and 165% over three years, and analyst forecasts for 27% annual growth, investors and the company's P/S ratio remain moderate, suggesting some skepticism about the sustainability of its growth compared to industry peers. The article highlights that while the company's P/S is in line with the industry, its superior revenue outlook isn't translating into a higher valuation, pointing to potential investor uncertainty.

New options for Alignment Healthcare (ALHC) with an August 2026 expiration have started trading, offering opportunities for investors due to the extended time value. This article highlights specific put and call contracts for ALHC, detailing potential strategies like selling a put for a lower cost basis or a covered call for increased returns, along with associated risks and implied volatilities.